Zynerba Pharmaceuticals, Inc. (ZYNE) Stock Overview
Explore Zynerba Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Zynerba Pharmaceuticals, Inc. (ZYNE)
Key Financials
Key Financials
Market Cap
70.1M
P/E Ratio
-1.59
EPS (TTM)
$-0.79
ROE
-0.59%
ZYNE Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Zynerba Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ZYNE on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.
Key metrics behind Zynerba Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -1.59 and a market capitalization of 70.1M. Combined with our AI analysis, these give both institutional and retail investors a clear view of ZYNE on the NASDAQ.